Since both HER2 and SphK1 are strong activators of survival signaling pathways, such as the MAPK pathway, and the HER2 signaling is highly autonomous, it is possible that negative feedback from HER2 signaling suppresses SphK1 activation in HER2-positive breast cancer. Here, ERBB2 is linked to breast cancer.